Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide. Immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 antibodies has shown promising results in the treatment of patients with advanced HCC. The anti-PD-1 antibody, nivolumab, is now approved for patien...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Immunol Immunother
Hlavní autoři: Brown, Zachary J., Yu, Su Jong, Heinrich, Bernd, Ma, Chi, Fu, Qiong, Sandhu, Milan, Agdashian, David, Zhang, Qianfei, Korangy, Firouzeh, Greten, Tim F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6085109/
https://ncbi.nlm.nih.gov/pubmed/29959458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-018-2190-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky